Skip to main content
. 2023 Jun 13;5(7):354–363. doi: 10.1002/acr2.11571

Figure 1.

Figure 1

Accrued duration of remission and proportion of patients in remission at Weeks 36 and 48 by historical ANCA status, baseline BVAS, and baseline VDI score. *Accrued number of weeks of remission over the 52‐week study period categorized in weeks (0, >0 to <12, 12 to <24, 24 to <36, and ≥36 weeks). †Remission was defined as BVAS equal to 0 and OG dose 4 mg/day or more of a prednisolone equivalent. ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CI, confidence interval; NA, not available—estimate could not be calculated because no patients in the placebo group achieved remission at Weeks 36 and 48; VDI, Vasculitis Damage Index.